Structural Changes in Hippocampal Subfields in Patients with Continuous Remission of Drug-Naive Major Depressive Disorder.
Adult
Antidepressive Agents
/ pharmacology
CA3 Region, Hippocampal
/ diagnostic imaging
Dentate Gyrus
/ diagnostic imaging
Depressive Disorder, Major
/ diagnostic imaging
Female
Follow-Up Studies
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Neuroimaging
Organ Size
Psychiatric Status Rating Scales
Remission Induction
antidepressant
brain morphology
cornu Ammonis
dentate gyrus
hippocampus
major depressive disorder
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Apr 2020
25 Apr 2020
Historique:
received:
03
03
2020
revised:
22
04
2020
accepted:
22
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
4
2
2021
Statut:
epublish
Résumé
Hippocampal volume is reduced in patients with major depressive disorder (MDD) compared with healthy controls. The hippocampus is a limbic structure that has a critical role in MDD. The aim of the present study was to investigate the changes in the volume of the hippocampus and its subfields in MDD patients who responded to antidepressants and subsequently were in continuous remission. Eighteen patients who met the following criteria were enrolled in the present study: the DSM-IV-TR criteria for MDD, drug-naïve at least 8 weeks or more, scores on the 17-items of Hamilton Rating Scale for Depression (HAMD) of 14 points or more, and antidepressant treatment response within 8 weeks and continuous remission for at least 6 months. All participants underwent T1-weighted structural MRI and were treated with antidepressants for more than 8 weeks. We compared the volumes of the hippocampus, including its subfields, in responders at baseline to the volumes at 6 months. The volumes of the whole hippocampus and the hippocampal subfields were measured using FreeSurfer v6.0. The volumes of the left cornu Ammonis (CA) 3 ( Increases in volume was observed in MDD patients who were in remission for at least 6 months.
Identifiants
pubmed: 32344826
pii: ijms21093032
doi: 10.3390/ijms21093032
pmc: PMC7246866
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Neuropharmacology. 2012 Jan;62(1):3-12
pubmed: 21807003
Nat Rev Neurosci. 2011 Sep 07;12(10):585-601
pubmed: 21897434
IEEE Trans Med Imaging. 1998 Feb;17(1):87-97
pubmed: 9617910
Nat Rev Neurosci. 2014 Mar;15(3):181-92
pubmed: 24552786
Curr Neuropharmacol. 2015;13(4):458-65
pubmed: 26412065
Eur Neuropsychopharmacol. 2012 Jan;22(1):1-16
pubmed: 21723712
Nat Commun. 2017 Jan 18;8:13624
pubmed: 28098162
Hippocampus. 2001;11(2):90-1
pubmed: 11345129
Sci Rep. 2018 Apr 3;8(1):5434
pubmed: 29615675
Biol Psychiatry. 2000 Jun 15;47(12):1087-90
pubmed: 10862809
Neuropsychiatr Dis Treat. 2019 Jun 06;15:1537-1545
pubmed: 31239688
Hippocampus. 2009 Jun;19(6):549-57
pubmed: 19405131
Arch Gen Psychiatry. 2000 Oct;57(10):925-35
pubmed: 11015810
Neuropsychopharmacology. 2016 Feb;41(3):791-801
pubmed: 26171720
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
J Affect Disord. 2016 Apr;194:21-9
pubmed: 26802503
Nat Commun. 2017 Nov 21;8(1):1668
pubmed: 29162814
Nat Commun. 2019 Aug 21;10(1):3768
pubmed: 31434877
Prog Neurobiol. 2011 Apr;93(4):457-67
pubmed: 21335052
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5
pubmed: 10984517
Mol Psychiatry. 2018 Aug;23(8):1737-1744
pubmed: 29133948
Biol Psychiatry. 2013 Jul 1;74(1):62-8
pubmed: 23419546
Nat Neurosci. 2007 Sep;10(9):1110-5
pubmed: 17726477
Psychopharmacology (Berl). 2014 Dec;231(23):4579-81
pubmed: 25326052
Mol Psychiatry. 2016 Jun;21(6):806-12
pubmed: 26122586
Int J Neuropsychopharmacol. 2014 Dec;17(12):1923-33
pubmed: 24969726
Am J Psychiatry. 2004 Apr;161(4):598-607
pubmed: 15056502
Neuropsychopharmacology. 2008 Jan;33(1):88-109
pubmed: 17851537
Cell Tissue Res. 2018 Jan;371(1):23-32
pubmed: 28828636
J Neurosci. 2007 May 2;27(18):4894-901
pubmed: 17475797
Eur Psychiatry. 2019 Apr;57:70-77
pubmed: 30721801
Int J Neuropsychopharmacol. 2014 Dec 07;18(5):
pubmed: 25522429
Psychiatry Res. 2013 Dec 30;214(3):197-203
pubmed: 24090511
Sci Rep. 2019 Jul 15;9(1):10166
pubmed: 31308432
Arch Gen Psychiatry. 2010 Oct;67(10):1002-11
pubmed: 20921116
Biol Psychiatry. 2011 Feb 15;69(4):326-35
pubmed: 21030008